Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

10x Genomics, Inc. Director's Dealing 2021

Jul 6, 2021

31830_dirs_2021-07-06_a969d377-4613-426f-871a-a9331a9604fd.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: 10x Genomics, Inc. (TXG)
CIK: 0001770787
Period of Report: 2021-07-01

Reporting Person: McAnear Justin J. (Chief Financial Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-07-01 Class A Common Stock M 10000 $5.04 Acquired 49370 Direct
2021-07-01 Class A Common Stock S 2700 $189.8522 Disposed 46670 Direct
2021-07-01 Class A Common Stock S 2800 $190.6638 Disposed 43870 Direct
2021-07-01 Class A Common Stock S 1500 $191.7347 Disposed 42370 Direct
2021-07-01 Class A Common Stock S 800 $192.9473 Disposed 41570 Direct
2021-07-01 Class A Common Stock S 1400 $193.7629 Disposed 40170 Direct
2021-07-01 Class A Common Stock S 700 $194.8054 Disposed 39470 Direct
2021-07-01 Class A Common Stock S 100 $195.82 Disposed 39370 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-07-01 Stock Option (right to buy) $5.04 M 10000 Disposed 2028-11-02 Class A Common Stock (10000) Direct

Footnotes

F1: This option exercise and the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F2: Includes an aggregate of 359 shares previously acquired under the Issuer's 2019 Employee Stock Purchase Plan.

F3: This transaction was executed in multiple trades at prices ranging from $189.24 to $190.18. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F4: This transaction was executed in multiple trades at prices ranging from $190.25 to $191.22. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F5: This transaction was executed in multiple trades at prices ranging from $191.32 to $192.29. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F6: This transaction was executed in multiple trades at prices ranging from $192.32 to $193.31. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F7: This transaction was executed in multiple trades at prices ranging from $193.38 to $194.35. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F8: This transaction was executed in multiple trades at prices ranging from $194.40 to $195.39. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F9: This option, originally for 600,000 shares, of which 189,841 shares have been exercised, vested as to one-fourth of the shares on October 8, 2019 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.